CLL Clinical Trial
Official title:
Allogeneic HSCT in 17p- CLL in First or Second Partial or Complete Remission at Transplant: a Non-interventional Prospective Study.
17p-/p53-mutated chronic lymphocytic leukemia (CLL) is an orphan disease, accounting for
approximately 5% of newly diagnosed CLL. This subgroup of patients has a very poor outcome
after chemoimmunotherapy. Allogeneic HCT may change the poor prognosis. In a retrospective
EBMT-analysis on 44 patients with advanced 17p-CLL 2-year progression-free survival was 45%
(95% CI, 30% to 60%) after allogeneic HCT (Allogeneic hematopoietic stem-cell transplantation
for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood
and Marrow Transplantation analysis. J Clin Oncol, 2008, 26, 5094-5100).
Referring to these favorable results and small additional series, patients with 17p-CLL
requiring therapy are considered to have an indication for allogeneic transplantation by many
CLL study groups. Several CLL study groups recommend allogeneic HCT in 17p-CLL as part of the
first- or second line treatment.
The aim is to collect additional evidence on allogeneic HCT in 17p-/p53-mutated CLL in first
or second remission by a non-interventional prospective study. Patients shall be registered
prior to HCT at the Leiden Office in order to rule out a reporting bias after
transplantation.
Objective:
The aim is to determine early PFS after allogeneic HCT in first or second remission of
17p-/p53-mutated CLL within an epidemiologic study.
Methods:
Neither the decision for allogeneic transplantation nor specific treatment recommendations
for patients with 17p-/p53-mutated CLL are part of the study. Instead, the study protocol
refers to EBMT guidelines. Indications for allogeneic stem cell transplantation in chronic
lymphocytic leukemia: the EBMT transplant consensus. Leukemia 21, 2007, 12-17). Minimal
essential data (MED) A and B, defined by the EBMT, will be collected (www.ebmt.org).
The rate of progression-free survival (PFS) at 1 year after HSCT was selected as primary
endpoint. Death, clinical relapse or progression but not immune manipulations (taper of
immunosuppression, DLI, rituximab) are considered as treatment failure for PFS. Patients
without information on one-year follow up will be considered as having experienced treatment
failure. The rate of PFS at 1 year will be calculated by dividing the number of patients
without treatment failure by the number of patients who met all selection criteria.
For the calculation of the sample size a fixed sample design was selected. The null
hypothesis is that the success-rate for PFS is equal or less than 50%. Referring to the
retrospective EBMT survey, PFS at one year after allogeneic HCT is expected to be 70%.
According to Fleming-A'Hern (1982) the null hypothesis can be rejected with a power of 80%
and an alpha error of 5% if a minimum of 24 out of 37 informative patients did not experience
treatment failure during the first year after allogeneic HCT (Machin et al, Sample Size
Tables for Clinical Studies, Wiley-Blackwell, 3rd edition, 2009). Taking into account a 10%
drop-out rate by violation of inclusion criteria the target number of patients to be included
was set at 41 patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02229422 -
A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03997968 -
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01862445 -
Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
|
||
| Completed |
NCT00535873 -
Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older
|
Phase 2 | |
| Withdrawn |
NCT03639324 -
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
|
Phase 1 | |
| Recruiting |
NCT05517265 -
Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
|
||
| Recruiting |
NCT03868722 -
Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04640909 -
Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients
|
N/A | |
| Recruiting |
NCT05610228 -
Study of the Metabolism in the Lymphatic Niche of CLL
|
||
| Completed |
NCT01168921 -
Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL)
|
Phase 2 | |
| Withdrawn |
NCT05209308 -
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
|
Phase 2 | |
| Completed |
NCT00792077 -
A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue
|
Phase 2 | |
| Recruiting |
NCT06073821 -
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
|
Phase 3 | |
| Recruiting |
NCT05246345 -
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
|
||
| Terminated |
NCT01532635 -
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
|
Phase 2 | |
| Completed |
NCT01703364 -
Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL
|
Phase 1/Phase 2 | |
| Terminated |
NCT03572634 -
Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL
|
Phase 1/Phase 2 | |
| Completed |
NCT03231579 -
Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
|
||
| Completed |
NCT00636909 -
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
|
Phase 2 | |
| Active, not recruiting |
NCT03524235 -
Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
|
Phase 1 |